Under construction – not a live service
Sign in
Not yet taking people in New ZealandPhase 1

Tests AB-110 for safety in healthy adults and adults with high blood pressure

Tests the safety of AB-110 in healthy adults and adults with high blood pressure.

Key facts

Who runs it
Antlia Bioscience, Inc
Where
Auckland, New ZealandSee the site
Trial code
Registry title
Study of AB-110 in Healthy and Hypertensive Participants
Status
Not yet recruiting
Phase
Phase 1
People taking part
104 people, planned
Started
Nov 2026
Expected to end
Sept 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Active drug
  • AB-110 Matching Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults without high blood pressure (Part A) and adults with high blood pressure who are otherwise healthy (Part B), to test the safety of a new drug, AB-110.

Age
Part A: 18 to 50 years. Part B: 18 to 65 years.
Sex
All sexes can join.
Disease stage
Part A: healthy, with systolic blood pressure of 130 or higher and below 140 mmHg. Part B: systolic blood pressure above 140 and up to 165 mmHg.
Earlier treatment
People who recently received an investigational agent cannot join.
Biomarker or test result
A normal 12-lead electrocardiogram (ECG) is needed. Kidney function (eGFR) must not be below 60 mL/min/1.73m^2.

Main reasons for not taking part

  • Secondary hypertension
  • Orthostatic hypotension
  • eGFR below 60 mL/min/1.73m^2
  • Recently received an investigational agent
  • Any past cardiovascular event

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Part A 18 - 50 years of age; Part B 18 -65 years of age
  • Part A SBP ≥130 and below 140mmHg and healthy; Part B >140 and ≤165 mmHg
  • Part A Body Mass Index in the range of 18 - 30 kg/m2, and minimal weight of 50 kg; Part B 18 - 32 kg/m2, and minimal weight of 50 kg
  • Has a normal 12-lead electrocardiogram (ECG)
  • Is a nonsmoker

Who cannot take part

  • Has recently received an investigational agent
  • Has secondary hypertension
  • Has history of any cardiovascular event
  • Has estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m\^2
  • Has orthostatic hypotension
  • Other inclusion/exclusion criteria may apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in New Zealand

  • AucklandHospital not named in the registryContact: Hanna KwakNo longer taking part

About the trial

What the trial wants to find out

This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with an optional cohort of BMI > 30 kg/m2 and ≤ 35 kg/m2 and multiple ascending dose (MAD; Part B) in participants with hypertension who are otherwise healthy. Sentinel dosing will be applied in the Part A study at each new dose level to ensure participant's safety.

Read full original descriptionShow less

The study will provide initial insight into the safety and tolerability of AB-110. In addition to safety, the study is designed to enable insights on secondary and exploratory research questions, including Blood Pressure (BP) reduction and exploratory biomarkers.

The 4 groups in the trial

  • Part A: Single Ascending Dose (SAD): AB-110Treatment being tested

    Participants will be administered a single dose of AB-110

    Treatment: Active drug

  • Part A: SAD: AB-110 Matching PlaceboPlacebo, for comparison

    Participants will be administered a single dose of AB-110 matching placebo

    Treatment: AB-110 Matching Placebo

  • Part B: Multiple Ascending Dose (MAD): AB-110Treatment being tested

    Participants will be administered multiple doses of AB-110

    Treatment: Active drug

  • Part B: MAD: AB-110 Matching PlaceboPlacebo, for comparison

    Participants will be administered multiple doses of AB-110 matching placebo

    Treatment: AB-110 Matching Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-110 in Healthy and Hypertensive Participants
Plain-language title
Tests AB-110 for safety in healthy adults and adults with high blood pressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07916961, who can take part
Record updated
4 November 2026